Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.
|Published (Last):||6 May 2005|
|PDF File Size:||20.84 Mb|
|ePub File Size:||2.89 Mb|
|Price:||Free* [*Free Regsitration Required]|
Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy? Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment. Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial.
Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
Relapsed adevrsos Refractory Acute Lymphoblastic Leukemia. Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Restricciones de tratamientos previos: Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p.
Subjects must have a serum creatinine level that is? IMP with orphan designation in the indication. Active treatment for graft-versus-host disease 6.
Committee on Advanced therapies CAT has issued a classification for this product. The IMP has been designated in this indication as an orphan drug in the Community. For these items you should use the l-aparaginasa and not add them to your search terms in the text field.
Adequate liver function, defined as both of the following: Date on which this record was first entered in the EudraCT database:. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition. Trials with results Trials without results. Subjects are under 18 years old.
A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells.
Karnofsky or Lansky scores? Pneumonia AND sponsor name. Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc.
The trial involves single site in the Member State concerned. Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7. Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To dfectos the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.
Review by the Competent Authority or Ethics Committee in the country concerned.
Combination product that includes a device, but does not involve an Advanced Therapy. Both Female Only Male L-asparagiinasa. Trials with results Trials without results Clear advanced search filters. How to search [pdf]. Known allergy to any of the drugs used in the study.
Clinical Trials Register
Age 18 years or younger at the time of study treatment initiation. Cancer AND drug name. Title of the trial for lay people, in easily understood, i. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Etectos duration of this interval must be approved by the Onyx study medical monitor.